[Symptomatic high chromogranin A level associated with rabeprazole and ranitidine].
Fraisse
Thibaut
T
Service de Médecine Interne C, CHU Carémeau, Nimes, France.
Pochic
Julie
J
Pinzani
Véronique
V
Balducchi
Jean Pierre
JP
Arnaud
Erik
E
de Wazières
Benoît
B
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects; D001562:Benzimidazoles / Q000009:adverse effects*; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives*; D064750:Rabeprazole; D011899:Ranitidine / Q000009:adverse effects*; D013276:Stomach Ulcer / Q000188:drug therapy*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins; D064750:Rabeprazole; D011899:Ranitidine; D009853:Omeprazole